Axelia Oncology develops AXA-042, a systemically-delivered TLR2/6 agonist that activates the innate immune system to generate anti-tumor responses in checkpoint-insensitive cancers. This approach targets a significant unmet need in oncology by reawakening immune mechanisms to overcome resistance to existing therapies and promote long-lasting responses in solid tumors.

BioScout provides AI-powered airborne particulate detection for agricultural disease management. This technology tracks pathogen spores before visible symptoms appear in crops, enabling immediate warnings for growers. The system helps optimize fungicide application, reduce preventative sprays, and improve overall farm efficiency.

Cardihab offers a digital cardiac rehabilitation platform that utilizes a clinician portal, virtual care plans, and user-friendly patient apps to deliver personalized care aligned with clinical guidelines. This solution addresses the low uptake and completion rates of traditional in-clinic cardiac rehabilitation programs by providing accessible support for patients recovering from heart events.

Certa Therapeutics is developing targeted GPR68 inhibitors to treat fibrotic diseases such as scleroderma and chronic kidney disease. Their therapies aim to reduce fibrosis progression, addressing the significant health risks associated with these life-threatening conditions.

Ena Respiratory is developing INNA-051, a first-in-class TLR2/6 agonist designed for self-administration via nasal delivery to enhance the innate immune response against respiratory viral infections. This product aims to reduce complications in at-risk populations by accelerating viral clearance and minimizing virus spread to the lower airways.

Ferronova has developed FerroTrace®, a mannose-labeled iron-oxide nanoparticle system designed for precise detection of high-risk lymph nodes in upper gastrointestinal cancers, enhancing surgical guidance and treatment planning. This technology addresses the challenge of accurately staging complex cancers, which is critical for improving patient survival rates.

Kinoxis Therapeutics develops small molecule therapeutics that target the oxytocin receptor to enhance social functioning and address social dysfunction in neurological and psychiatric disorders. Their lead candidate, KNX100, is designed for substance use disorders and has completed Phase I clinical trials, aiming to improve recovery outcomes for affected individuals.

Lenexa Medical develops the LenexaCARE® system, which utilizes embedded fabric-based sensor technology to monitor patient positioning and pressure in real-time, significantly reducing the risk of pressure injuries in healthcare settings. This solution addresses the high incidence of preventable pressure injuries, which cost the Australian healthcare system over $9 billion annually, by providing clinicians with actionable data for timely interventions.

Morse Micro develops Wi-Fi HaLow technology, providing robust, secure, and energy-efficient wireless communication solutions operating in the sub-1 GHz band. This technology enables extended range and superior penetration for a wide array of Internet of Things (IoT) applications, including smart cities and industrial environments. Their integrated Wi-Fi HaLow System-on-Chip (SoC) simplifies deployment for connecting billions of low-power devices.

NatureHelm offers a biodiversity intelligence platform that aggregates species data and links it to business activities. This enables organizations to assess, prioritize, and manage nature-related risks and dependencies across their operations and value chains, supporting regulatory compliance and sustainability.

The startup produces probiotic beverages that utilize microgel technology to withstand stomach acid, ensuring higher survival rates of probiotics compared to traditional formulations. This enhanced delivery mechanism supports weight management and gut health, ultimately boosting immune function.